Polymer-doxorubicin Conjugates: Redefining Chemotherapy for Breast Cancer

Polymer drug conjugates (PDCs) represent a targeted modification of conventional chemotherapeutics, transforming small-molecule drugs like doxorubicin (dox) into macromolecular structures with significantly altered biological properties. By incorporating a biocompatible polymer backbone, a cleavable linker, and an active cytotoxic payload, PDCs achieve prolonged systemic persistence, advantageous biodistribution, and tumor-specific release. This architecture facilitates more reliable exploitation of the enhanced permeability and retention (EPR) effect, thereby encouraging preferential intratumoral accumulation while reducing off-target exposure. The regulated and microenvironment-sensitive release of dox provides a logical approach to mitigate cardiotoxicity, a significant limitation of anthracycline treatment. PDCs can partially bypass efflux-mediated multidrug resistance by using endocytic uptake pathways rather than transporter-dependent mechanisms. Prototypical systems such as HPMA-dox and PEG-dox offer persuasive translational evidence that macromolecular conjugation can enhance the therapeutic index of dox. PDCs collectively demonstrate how advanced molecular engineering might rejuvenate traditional chemotherapeutics for contemporary oncology.